Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: A comparison with the effects of alfacalcidol

Experimental Animals

Volumn 55, Issue 4, 2006, Pages 333-342

  Iwamoto, Jun ^a   Seki, Azusa ^b   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^c   Yamada, Harumoto ^d   Yeh, James K ^e  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hamri Co Ltd   (Japan)

^c Mitate Hospital   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Alfacalcidol; Osteopenia; Ovariectomy; Rat; Risedronate

Indexed keywords

ALFACALCIDOL; ONE ALFA; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE EROSION; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; DIAPHYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEMUR; METAPHYSIS; NONHUMAN; OSSIFICATION; OSTEOPENIA; OVARIECTOMY; RAT; RAT STRAIN; TIBIA;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DISEASE MODELS, ANIMAL; ETIDRONIC ACID; FEMALE; HYDROXYCHOLECALCIFEROLS; OSTEOGENESIS; OVARIECTOMY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33746950895     PISSN: 13411357     EISSN: 13411357     Source Type: Journal    
DOI: 10.1538/expanim.55.333     Document Type: Article

References (20)

1. 3. Endocr. Rev. 6:491-511.
2. Chappard, D., Petitjean, M., Alexandre, C., Vico, L., Minaire, P., and Riffat, G. 1991. Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts. J. Bone Miner. Res. 6: 673-680.
3. Cranney, A., Guyatt, G., Griffith, L., Wells, G., Tugwell, P., and Rosen, C. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23: 570-578.
4. Eastell, R. and Riggs, B.L. 1997. Vitamin Dosteoporosis. pp. 695-711, In:Vitamin D (Feldman, D., Glorieux, F.H., Pike, J.W. eds.), Academic Press, New York.
5. Erben, R.G. 1997. Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J. Histochem. Cytochem. 45: 307-313.
6. 3. J. Bone Miner. Res. 17: 1499-1511.
7. Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., and Reginster, J.Y. 2000. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J. Clin. Endocrinol. Metab. 85: 1895-1900.
8. Harris, S.T., Watts, N.B., Genant, H.K., McKeever, C.D., Hangartner, T., Keller, M., Chesnut, C.H.III., Brown, J., Eriksen, E.F., Hoseyni, M.S., Axelrod, D.W., and Miller, P.D. 1999. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 282: 1344-1352.
9. Ito, M. 2002. Bone mass, microstructure, and quality with bone strength - The effects of antiresorptive agents -. J. Jpn. Soc. Bone Morphom. 12: 51-54 (in Japanese).
10. 2 on cortical and cancellous bones in orchidectornized and /or sciatic neurectomized rats. J. Bone Miner. Res. 18: 776-783.
11. 2 combine to improve the femoral neck strength of ovariectomized rats. Calcif. Tissue Int. 77: 119-126.
12. McClung, M.R., Geusens, P., Miller, P.D., Zippel, H., Bensen, W.G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., Meunier, P.J., and Reginster, J.Y. Hip Intervention Program Study Group. 2001. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344: 333-340.
13. Mosekilde, L., Thomsen, J.S., Mackey, M.S., and Phipps, R.J. 2000. Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 27: 639-645.
14. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 54: 370-76.
15. 2. J. Bone Miner. Metab. 22: 404-414.
16. Parfitt, A.M., Drezner, M.K., Glorieux, F.H., Kanis, J.A., Malluche, H., Meunier, P.J., Ott, S.M., and Recker, R.R. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASMBR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2: 595-610.
17. Reichel, H., Koeffler, H.P., and Norman, A.W. 1989. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 320:980-991.
18. Rogers, M.J., Frith, J.C., Luckman, S.P., Coxon, F.R., Benford, H.L., Monkkonen, J., Auriola, S., Chilton, K.M., and Russell, R.G.G. 1999. Molecular mechanism of action of bisphosphonate. Bone 24 (5 Suppl): 73S-79S.
19. Seeman, E. 2003. Periosteal bone formation - a neglected determinant of bone strength. N. Engl. J. Med 349: 320-323.
20. Shiraishi, A., Takeda, S., Masaki, T., Higuchi, Y., Uchiyama, Y., Kubodera, N., Sato, K., Ikeda, K., Nakamura, T., Matsumoto, T., and Ogata, E. 2000. Alfacalcidol inhibits bone resorption and stimulate formation in an ovariectomized rats model of osteoporosis: distinct actions from estrogen. J. Bone Miner. Res. 15: 770-779.